Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT03964506Early Phase 1Recruiting

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Role: lead

NCT03398200Phase 2Completed

Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma

Role: lead

All 2 trials loaded